TrialThe oncologist2015

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.

Valentina Guarneri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.